ClinicalTrials.gg
CompletedNCT07186920Updated Feb 11, 2026

Lung Ultrasound Assessment of Postoperative Atelectasis After Mechanical Ventilation With Minimum Driving Pressure

An interventional study of PEEP titration for Minimum Driving Pressure and Lung Protective Ventilation in Postoperative Atelectasis, Postoperative Pulmonary Atelectasis and Postoperative Pulmonary Complications (PPCs), sponsored by University General Hospital of Patras. Completed at 1 site in Greece. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-11.

Sponsored by University General Hospital of Patras · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Brief summary The goal of this clinical trial is to compare two different types of perioperative mechanical ventilation (MV), specifically Protective Mechanical Ventilation (PMV) and MV with the lowest possible Driving Pressure (ΔP), in relation to the appearance of postoperative lung closing, eg atelectasis, in adult patients who are operated. Atelectasis will be evaluated via lung ultrasound.

The main questions it aims to answer are:

  • Is MV with lower ΔP better than conventional PMV in keeping lungs more open perioperatively and immediately postoperatively?
  • Does MV with lower ΔP decrease hospital stay, Intensive Care Unit (ICU) need and mortality?

Researchers will use lung ultrasound to compare MV with the lowest possible Driving Pressure (ΔP) to Protective Mechanical Ventilation (PMV) to see if any of this is more protective than the other concerning lung atelectasis.

All participants will receive perioperative MV.

Half of them will receive conventional Protective Mechanical Ventilation (PMV). This will include well known generally protective settings for mechanical ventilation of patients, concerning volumes, pressures, respiratory rate, inspiratory gases and ventilation maneuvers.

The rest of participants will be ventilated with the lowest possible Driving Pressure (ΔP). This will be similar to PMV in the chosen volumes, respiratory rate, inspiratory gases and ventilation maneuvers. However, the pressure inside lung at the end of expiration, eg Positive End Expiratory Pressure (PEEP), will be not be preset for every patient. Initially, we will perform a maneuver that will quantify each individual's lung characteristics and mechanics. According to this, we will find the exact PEEP that seems to suit each patients lungs most, and use this perioperatively, trying to provide lungs the best conditions every time.

After the completion of the operation, all the patients will be screened for atelectasis, via lung ultrasound, using a well established protocol for the quantification of atelectasis. The results will be statistically analyzed trying to find if any of the forementioned strategies of mechanical ventilation surpasses the other concerning atelectasis appearance.

Furthermore efficiency of lung oxygen absorption, hospital stay, ICU need and mortality will be noted.

02

Conditions studied

  • Postoperative Atelectasis
  • Postoperative Pulmonary Atelectasis
  • Postoperative Pulmonary Complications (PPCs)
  • Lung Ultrasonography Score
  • Lung Ultrasound

Browse trials for

Keywords

  • Postoperative Atelectasis
  • Postoperative Pulmonary Atelectasis
  • Postoperative pulmonary complications (PPCs)
  • Lung ultrasonography score
  • Lung ultrasound
  • Atelectasis
  • Pulmonary atelectasis
03

In context

Pulmonary Atelectasis

377 studies on the registry are indexed under Pulmonary Atelectasis; 93 are open to participants now.

This study's enrollment of 70 is above the median of 60 across 268 interventional studies indexed under Pulmonary Atelectasis.

Browse Pulmonary Atelectasis studies →

Lead sponsor

University General Hospital of Patras is the lead sponsor of 4 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • >17 years old
  • Surgery with general anesthesia \& invasive mechanical ventilation
  • I-III

Exclusion criteria

Exclusion Criteria:

  • \<18 years old
  • Preoperative ARISCAT score estimation \<26
  • Women during pregnancy or just given birth
  • Other type of anesthesia (Not general)
  • of administration of neuromuscular blockade agents.
  • Contraindication of cease of spontaneous ventilation.
  • Mechanical ventilation without endotracheal intubation.
  • Severe heart failure / History of ischemic heart disease.
  • Moderate or severe chronic obstructive lung disease or interstitial lung disease.
  • History of operation in heart, lung or diaphragm.
  • Presence of new active pathology in respiratory system at the beginning of surgery (infection / trauma / anatomic disorder).
  • Severe intraoperative respiratory complication (laryngospasm / bronchospasm / anaphylaxis).
  • Immediate postoperative need for continuation of IMV.
  • Patient denial of participation in the trial.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
70 participants (actual)

Study arms

  • Other
    Lung Protective Ventilation

    CONVENTIONAL LUNG PROTECTIVE VENTILATION This group is mechanically ventilated with Invasive Mechanical Ventilation with PEEP 8 cm H20 Tidal Volume (VT) 8 ml/kg Ideal Body Weight (IBW) Respiratory Rate (RR) --\> PaCO2 = 35-45 mmHg Inspired Oxygen Fraction (FiO2) 0.4 - 0.5 --\> Pulse Saturation Oxygen (SpO2) \> 93% Recruitment Maneuver (as described) every hour

    Procedure: Lung Protective Ventilation

  • Active comparator
    Minimum Driving Pressure

    This group is mechanically ventilated with Invasive Mechanical Ventilation with PEEP; Initially 8 cm H20, titrated at level with Minimum Driving Pressure after first recruitment - titration maneuver followed by new recruitment maneuver VT 8 ml/kg IBW RR --\> PaCO2 = 35-45 mmHg FiO2 0.4 - 0.5 --\> SpO2 \> 93% Recruitment Maneuver (as described) every hour

    Procedure: PEEP titration for Minimum Driving Pressure

Interventions

  • ProcedurePEEP titration for Minimum Driving Pressure

    This group is mechanically ventilated with Invasive Mechanical Ventilation with Volume Control Ventilation mode with PEEP Initially 8 cm H2O. Afterwards, the lungs are recruited with the aforementioned maneuver. During subsequent derecruitment, PEEP is decreased by 2 cm H20 and compliance is noted in each stage. The goal is to find PEEP with maximum compliance (Cmax). A new recruitment maneuver follows and during derecruitment PEEP is set at the optimum value that was previously defined. VT 8 ml/kg IBW RR --\> PaCO2 = 35-45 mmHg FiO2 0.4 - 0.5 --\> SpO2 \> 93% Recruitment Maneuver (as described) every hour

    Also known as: Maximum compliance mechanical ventilation, Cmax Mechanical Ventilation

  • ProcedureLung Protective Ventilation

    This group is mechanically ventilated with Invasive Mechanical Ventilation with Volume Control Ventilation mode with PEEP 8 cm H2O. VT 8 ml/kg IBW RR --\> PaCO2 = 35-45 mmHg FiO2 0.4 - 0.5 --\> SpO2 \> 93% Recruitment Maneuvers (as described) every hour

06

What researchers measure

Primary outcomes

  1. Lung Ultrasound Score (LUS)

    12 Position Lung Ultrasound will be performed in Post Anesthesia Care Unit (PACU) within 20 minutes postoperatively. In each position the potential scores will be 0,1,2 and 3. 0 --\> 0-2 B-lines 1. --\> \>2 B-lines or presence of small sublpleural consolidations with normal pleural line. 2. --\> Multiple coalescent B-lines or multiple small sublpleural consolidations with thickened or irregular pleural line. 3. --\> Total air loss or subpleural consolidation with diameter bigger than 1x2cm. The total sum of ultrasound scores of each position is marked as LUS.

    Time frame: Within 20 minutes in PACU.

Secondary outcomes

  1. Rate of Postoperative Respiratory Failure

    Postoperative Respiratory Failure based on Arterial Blood Gases in PACU (type I and/or II) Type I --\> Arterial Oxygen Partial Pressure / Arterial Oxygen Saturation (P/F) ratio \<300 Type II --\> PaCO2 \> 45mmHg

    Time frame: Within 30 minutes in PACU

  2. Rate of NIMV need

    Potential need for NIMV in PACU due to Respiratory Failure. CPAP / BIPAP / High-Flow Nasal Canula

    Time frame: Period of stay in Post Anesthesia Care Unit (PACU). From time of postoperative transfer to PACU until time of discharge from PACU and return to general clinic, an average of 1 hour.

  3. Hospital Stay

    Total hospital stay days from day of operation until hospital discharge.

    Time frame: From day of operation until the end of patient stay inside hospital, because of return to home or due to death.

  4. ICU need.

    Potential Need for ICU admission.

    Time frame: From day of operation until the end of patient stay inside hospital, because of return to home or due to death.

  5. ICU stay

    In case of ICU need, total days of ICU stay.

    Time frame: From day of operation until the end of patient stay inside hospital, because of return to home or due to death.

  6. 28 Day mortality

    Incidence of death in 28 days in each group.

    Time frame: From day of operation until up to 28 days.

  7. Mechanical Power (MP)

    o To calculate MP, the following must be recorded: RR, Peak Airway Pressure (Ppeak), Plateau Pressure (Pplat), and PEEP. The simplified equation will be used; MP = 0.098 × RR × \[Ppeak - (Plat-PEEP)/2\]

    Time frame: From the moment of beginning of operation until the moment of the end of operation and mechanical ventilation

  8. Volume-normalized Mechanical Power (MPcrs)

    MPcrs = MP/Respiratory System Compliance (Crs)

    Time frame: From the moment of beginning of operation until the moment of the end of operation and mechanical ventilation

  9. Elastic Power (EP)

    To calculate EP, the following must be recorded: RR, VT, Pplat, and PEEP. The following equation will be used: EP = 0.098 × RR × VT × \[(Plat+PEEP)/2\]

    Time frame: From the moment of beginning of operation until the moment of the end of operation and mechanical ventilation

  10. Volume-normalized Elastic Power (EPcrs)

    EPcrs = EP/Crs

    Time frame: From the moment of beginning of operation until the moment of the end of operation and mechanical ventilation

07

Study locations

1 site
  • University Hospital of Patras
    Pátrai, 26504, Greece
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07186920
Lead sponsor
University General Hospital of Patras
Responsible party
Antonios Kostouros (Anesthesiology Resident, Antonios Kostouros, University General Hospital of Patras) — Principal investigator
First posted
Sep 22, 2025
Start date
Oct 6, 2025
Primary completion
Dec 31, 2025
Completion
Jan 15, 2026
Last update
Feb 11, 2026

Study contacts

Diamanto Aretha, A. Professor
study chair · University of Patras
Nektaria Xirouchaki, Consultant
study director · University of Crete
Eumorfia Kondili, Professor
study director · University of Crete
Antonios Kostouros, Resident
principal investigator · University of Patras

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion